Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Has stem cell transplantation come of age in the treatment of sickle cell disease?

Bone Marrow Transplantation volume 40, pages 813–821 (2007)Cite this article

Abstract

Currently, hematopoietic SCT (HCT) is the only intervention that can restore normal hematopoiesis to provide a ‘cure’ in sickle cell disease. Yet, this treatment modality is used sparsely—a total of less than 400 transplants are reported in the Center for International Blood and Marrow Transplant Research database despite 70 000 afflicted in the United States; 88% of transplants are from HLA-matched sibling donors and 84% are <16 years of age at transplant. Overall survival at 3 years is over 90% after HCT in the young but 62% in adult HCT recipients due to increased disease and transplant-related morbidity. The decision and timing of HCT is a dilemma for physicians and families due to the need to consider HCT before severe organ damage in a disease that is generally not fatal in children with adequate supportive care. From the transplant physician's perspective, however, advances in the ability to identify well-matched donors, supportive care and promising conditioning regimens with low toxicity and transplant complications support the development of new HCT trials for sickle cell disease as the risk/benefit ratio can be balanced better. With the recognition of new predictors of early mortality, the anticipation of extensive and expensive life-long medical support, and the poor quality of life despite medical care, the scales tip in favor of HCT. This is prime time for the development of careful unrelated donor HCT trials for sickle cell disease. Research efforts targeting HCT will need to be directed at seeking safe and effective transplant methods applicable to all patients who might derive benefit.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Johnson F . Bone marrow transplantation in the treatment of sickle cell anemia. Am J Pediatr Hematol Oncol 1985; 7: 254–257.

    Article  CAS  PubMed  Google Scholar 

  2. Ashley-Koch A, Yang Q, Olney R . Sickle hemoglobin (HbS) A allele and sickle cell disease. Am J Epidemiol 2000; 151: 839–845.

    Article  CAS  PubMed  Google Scholar 

  3. Ohene-Frempong K, Weiner S, Sleeper L . Cerebrovascular accidents in sickle cell disease rates and risk factors. Blood 1998; 91: 288–294.

    CAS  PubMed  Google Scholar 

  4. Scothorn D, Price C, Schwartz D . Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr 2002; 140: 348–354.

    Article  PubMed  Google Scholar 

  5. Gladwin M, Sachdev V, Jison M, Shizukuda Y, Plehn J, Minter K et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350: 886–895.

    Article  CAS  PubMed  Google Scholar 

  6. Kato G, McGowan V, Machado R, Little J, Taylor VI J, Morris C et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006; 107: 2279–2285.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Hankins J, Ware R, Rogers Z, Wynn L, Lane P, Scott J et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 2005; 106: 2269–2275.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Boyd J, Macklin E, Strunk R, DeBaun M . Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood 2006; 108: 2923–2927.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Wang W, Morales K, Scher C, Styles L, Olivieri N, Adams R et al. Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. J Pediatr 2005; 147: 244–247.

    Article  PubMed  Google Scholar 

  10. Pai V, Nahata M . Duration of penicillin prophylaxis in sickle cell anemia: issues and controversies. Pharmacotherapy 2000; 20: 110–117.

    Article  CAS  PubMed  Google Scholar 

  11. Miller S, Sleeper L, Pegelow C, Enos L, Wang W, Weiner S et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000; 342: 83–89.

    Article  CAS  PubMed  Google Scholar 

  12. Miller S, Macklin E, Pegelow C, Kinney T, Sleeper L, Bello J et al. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr 2001; 139: 385–390.

    Article  CAS  PubMed  Google Scholar 

  13. Quinn C, Shull E, Ahmad Lee N, Rogers Z, Buchanan G . Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia. Blood 2007; 109: 40–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Quinn C, Miller S . Risk factors and prediction of outcomes in children and adolescents who have sickle cell anemia. Hematol Oncol Clin North Am 2004; 18: 1339–1354.

    Article  PubMed  Google Scholar 

  15. Platt O, Brambilla D, Rosse W, Milner P, Castro O, Steinberg M et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639–1644.

    Article  CAS  PubMed  Google Scholar 

  16. Powars D, Chan L, Hiti A, Ramicone E, Johnson C . Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore) 2005; 84: 363–376.

    Article  Google Scholar 

  17. Quinn C, Rogers Z, Buchanan G . Survival of children with sickle cell disease. Blood 2004; 103: 4023–4027.

    Article  CAS  PubMed  Google Scholar 

  18. McClish D, Penberthy L, Bovbjerg V, Roberts J, Aisiku I, Levenson J et al. Health related quality of life in sickle cell patients: the PiSCES project. Health Qual Life Outcomes 2005; 3: 50.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Nietert P, Silverstein M, Abboud M . Sickle cell anemia: epidemiology and cost of illness. Pharmacogenomics 2002; 20: 357–366.

    Google Scholar 

  20. Walters M . Stem cell therapy for sickle cell disease: transplantation and gene therapy. Am Soc Hematol Educ Manual 2005, 66–73.

    Article  Google Scholar 

  21. Sadelain M . Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia. Curr Opin Hematol 2006; 13: 142–148.

    Article  CAS  PubMed  Google Scholar 

  22. Walters M, Patience M, Leisenring W, Rogers Z, Aquino V, Buchanan G et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 2001; 7: 665–673.

    Article  CAS  PubMed  Google Scholar 

  23. Gaziev J, Sodani P, Polchi P, Andreani M, Lucarelli G . Bone marrow transplantation in adults with thalassemia: treatment and long-term follow up. Ann N Y Acad Sci 2005; 1054: 196–205.

    Article  PubMed  Google Scholar 

  24. LaNasa G, Giardini C, Argiolu F, Locatelli F, Arras M, De Stefano P et al. Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood 2002; 99: 4350–4356.

    Article  CAS  Google Scholar 

  25. Sodani P, Gaziev D, Polchi P, Erer B, Giardini C, Angelucci E et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood 2004; 104: 1201–1203.

    Article  CAS  PubMed  Google Scholar 

  26. La Nasa G, Argiolu F, Giardini C, Pession A, Fagioli F, Caocci G et al. Unrelated bone marrow transplantation for {beta}-thalassemia patients: the experience of the Italian Bone Marrow Transplant Group. Ann N Y Acad Sci 2005; 1054: 186–195.

    Article  PubMed  Google Scholar 

  27. Jaing T, Hung I, Yang C, Chen S, Sun C, Chow R . Rapid and complete donor chimerism after unrelated mismatched cord blood transplantation in 5 children with beta-thalassemia major. Biol Blood and Marrow Transplant 2005; 11: 349–353.

    Article  Google Scholar 

  28. Hoppe C, Walters M . Bone marrow transplantation in sickle cell anemia. Curr Opin Oncol 2001; 13: 85–90.

    Article  CAS  PubMed  Google Scholar 

  29. Steen R, Helton K, Horwitz E, Benaim E, Thompson S, Bowman L et al. Improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts. Ann Neurol 2001; 49: 222–229.

    Article  CAS  PubMed  Google Scholar 

  30. Woodard P, Helton K, Khan R, Hale G, Phipps S, Wang W et al. Brain parenchymal damage after hematopoietic stem cell transplantation for severe sickle cell disease. Br J Haematol 2005; 129: 550–552.

    Article  PubMed  Google Scholar 

  31. Kalinyak K, Morris C, Ball W, Ris M, Harris R, Rucknagel D . Bone marrow transplantation in a young child with sickle cell anemia. Am J Hematol 1995; 48: 256–261.

    Article  CAS  PubMed  Google Scholar 

  32. Walters M, Storb R, Patience M, Leisenring W, Taylor T, Sanders J et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000; 95: 1918–1924.

    CAS  PubMed  Google Scholar 

  33. Eggleston B, Patience M, Edwards S, Adamkiewicz T, Buchanan G, Davies S et al. Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anemia. Br J Haematol 2007; 136: 673–676.

    Article  CAS  PubMed  Google Scholar 

  34. Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990; 50: 6203–6207.

    CAS  PubMed  Google Scholar 

  35. Essel J, Thompson J, Harman G, Halvorson R, Snyder M, Johnson R et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft versus host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 1992; 79: 2784–2788.

    Google Scholar 

  36. Beinert T, Dull T, Wolf K, Holler E, Vogelmeier C, Behr J et al. Late pulmonary impairment following allogeneic bone marrow transplantation. Eur J Med Res 1996; 1: 343–348.

    CAS  PubMed  Google Scholar 

  37. Vermylen C, Cornu G, Ferster A, Brichard B, Ninane J, Ferrant A et al. Hematopoietic stem cell transplantation for sickle cell anemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998; 22: 1–6.

    Article  CAS  PubMed  Google Scholar 

  38. Bernaudin F, Souillet G, Vannier J, Plouvier E, Lemerle S, Michel G et al. Treatment of severe forms of sickle cell anemia with bone marrow allograft: French experience (15 cases). Nouv Rev Fr Hematol 1993; 35: 319–323.

    CAS  PubMed  Google Scholar 

  39. Locatelli F, Rocha V, Reed W, Bernaudin F, Ertem M, Grafakos S et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003; 101: 2137–2143.

    Article  CAS  PubMed  Google Scholar 

  40. Panepinto J, Walters M, Carreras J, Marsh J, Bredeson C, Gale R et al. Matched-related transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol 2007; 137: 479–485.

    Article  PubMed  Google Scholar 

  41. Adamkiewicz T, Mehta P, Boyer M, Kedar A, Olson T, Olson E et al. Transplantation of unrelated placental blood cells in children with high-risk sickle cell disease. Bone Marrow Transplant 2004; 34: 405–411.

    Article  CAS  PubMed  Google Scholar 

  42. Walters M, Quirolo L, Trachtenberg E, Edwards S, Hale L, Lee J et al. Sibling donor cord blood transplantation for thalassemia: Experience of the Sibling Donor Cord Blood Program. Ann N Y Acad Sci 2005; 1054: 206–213.

    Article  PubMed  Google Scholar 

  43. Walters M, Sullivan K, Bernaudin F, Souillet G, Vannier J, Johnson F et al. Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. Blood 1995; 85: 879–884.

    CAS  PubMed  Google Scholar 

  44. van Besien K, Bartholomew A, Stock W, Peace D, Devine S, Sher D et al. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant 2000; 26: 445–449.

    Article  CAS  PubMed  Google Scholar 

  45. Schleuning M, Stoetzer O, Waterhouse C, Schlemmer M, Ledderhose G, Kolb H . Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment for sickle cell disease. Exp Hematol 2002; 30: 7–10.

    Article  PubMed  Google Scholar 

  46. Iannone R, Casella J, Fuchs E, Chen A, Jones R, Woolfrey A et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 2003; 9: 519–528.

    Article  PubMed  Google Scholar 

  47. Horan J, Liesveld J, Fenton P, Blumberg N, Walters M . Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant 2005; 35: 171–177.

    Article  CAS  PubMed  Google Scholar 

  48. Jacobsohn D, Duerst R, Tse M, Kletzel M . Reduced intensity hematopoietic stem-cell transplantation. Lancet 2004; 364: 156–162.

    Article  PubMed  Google Scholar 

  49. Mazur M, Kurtzberg J, Halperin E, Ciocci G, Szabolcs P . Transplantation of a child with sickle cell anemia with an unrelated cord blood unit after reduced intensity conditioning. J Pediatr Hematol Oncol 2006; 28: 840–844.

    Article  CAS  PubMed  Google Scholar 

  50. Krishnamurti L, Blazar B, Wagner J . Bone marrow transplantation without myeloablation for sickle cell disease. N Engl J Med 2001; 344: 68.

    Article  CAS  PubMed  Google Scholar 

  51. Zimring J, Hair G, Deshpande S, Horan J . Immunization to minor histocompatibility antigens on transfused RBCs through crosspriming into recipient MHC class I pathways. Blood 2006; 107: 187–189.

    Article  CAS  PubMed  Google Scholar 

  52. Dodero A, Carrabba M, Milani R, Rizzo E, Raganato A, Montefusco V et al. Reduced intensity conditioning containing low dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased by T-cell reconstitution is delayed. Exp Hematol 2005; 33: 920–927.

    Article  CAS  PubMed  Google Scholar 

  53. Shenoy S, Grossman W, DiPersio J, Yu L, Wilson D, Barnes Y . A novel reduced-intensity stem cell transplant regimen for non-malignant disorders. Bone Marrow Transplant 2005; 35: 345–352.

    Article  CAS  PubMed  Google Scholar 

  54. Schrezenmeier H, Passweg J, Marsh J, Bacigalupo A, Bredeson C, Bullorsky E et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HAL-matched sibling donor transplants for young patients with severe acquired aplastic anemia: a report from the European Group for Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research. Blood 2007 [E-pub ahead of print, May 2].

  55. Bunin N, Aplenc R, Grupp S, Pierson G, Monos D . Unrelated donor or partially matched related donor peripheral stem cell transplant with CD34+ selection and CD3+ addback for pediatric patients with leukemias. Bone Marrow Transplant 2006; 37: 143–149.

    Article  CAS  PubMed  Google Scholar 

  56. Tabilio A, Falzetti F, Zei T, De Ioanni M, Bonifacio E, Battelli F et al. Graft engineering for allogeneic haploidentical stem cell transplantation. Blood Cells Mol Dis 2004; 33: 274–280.

    Article  PubMed  Google Scholar 

  57. Wall D, Carter S, Kernan N, Kapoor N, Kamani N, Brochstein J et al. Busulphan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. Biol Blood and Marrow Transplant 2005; 11: 637–646.

    Article  CAS  Google Scholar 

  58. Wagner J, Barker J, DeFor T, Baker K, Blazar B, Eide C et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant disease: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100: 1611–1618.

    CAS  PubMed  Google Scholar 

  59. Barker J, Scaradavou A, Stevens C, Rubinstein P . Analysis of 608 umbilical cord blood (UCB) transplants: HLA-Match is a critical determinant of transplant related mortality (TRM) in the post-engraftment period even in the absence of acute graft versus host disease (aGVHD). Blood 2005; 106, Abstract 303.

  60. Kodish E, Lantos J, Stocking C, Singer P, Siegler M, Johnson F . Bone marrow transplantation for sickle cell disease. A study of parents' decisions. N Engl J Med 1991; 325: 1349–1353.

    Article  CAS  PubMed  Google Scholar 

  61. Walters M, Patience M, Leisenring W, Eckman J, Buchanan G, Rogers Z et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood and Marrow Transplant 1996; 2: 100–104.

    CAS  Google Scholar 

  62. Chakrabarti S, Bareford D . A survey on patient perception of reduced-intensity transplantation in adults with sickle cell disease. Bone Marrow Transplant 2007; 39: 447–451.

    Article  CAS  PubMed  Google Scholar 

  63. van Besien K, Koshy M, Anderson-Shaw L, Talishy N, Dorn L, Devine S et al. Allogeneic stem cell transplantation for sickle cell disease. A study of parents' decisions. Bone Marrow Transplant 2001; 28: 545–549.

    Article  CAS  PubMed  Google Scholar 

  64. Mentzer W, Heller S, Pearle P, Hackney E, Vichinsky E . Availability of related donors for bone marrow transplantation in sickle cell anemia. Am J Pediatr Hematol Oncol 1994; 16: 27–29.

    CAS  PubMed  Google Scholar 

  65. Krishnamurti L, Abel S, Maiers M, Flesch S . Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies. Bone Marrow Transplant 2003; 31: 547–550.

    Article  CAS  PubMed  Google Scholar 

  66. Adamkiewicz T, Boyer M, Bray R, Haight A, Yeager A . Identification of unrelated cord blood units for hematopoietic stem cell transplantation in children with sickle cell disease. J Pediatr Hematol Oncol 2006; 28: 29–32.

    PubMed  Google Scholar 

  67. Stevens C, Scaradavou A, Carrier C, Carpenter C, Rubinstein P . An empirical analysis of the probability of finding a well matched cord blood unit: implications for a national cord blood inventory. Blood 2005; 106, Abstract 2047.

  68. Gratwohl A, Baldomero H, Schwendener A, Gratwohl M, Urbano-Ispizua A, Frauendorfer K . Hematopoietic stem cell transplants for chronic myeloid leukemia in Wurope—impact of cost considerations. Leukemia 2007; 21: 383–386.

    Article  CAS  PubMed  Google Scholar 

  69. Gajewski J, Robinson P . Do affluent societies have the only options for the best therapy? Leukemia 2007; 21: 387–388.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Hematology-Oncology, Washington University School of Medicine and St Louis Children's Hospital, St Louis, MO, USA

    S Shenoy

Authors
  1. S Shenoy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Shenoy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shenoy, S. Has stem cell transplantation come of age in the treatment of sickle cell disease?. Bone Marrow Transplant 40, 813–821 (2007). https://doi.org/10.1038/sj.bmt.1705779

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705779

Keywords

This article is cited by

Search

Advanced search

Quick links